Zeo ScientifiX, Inc. (ZEOX) stock
ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
$0.91+0.00 (+0.15%)
Close on Oct 19, 2026Market cap $7.08MP/E –Yield –
Zeo ScientifiX operating margin
Operating margin is operating income as a percentage of revenue.
Zeo ScientifiX's operating margin for the twelve months ending Apr 30, 2026 was -59.1%. For fiscal 2025 it was -103.6%, against -115.1% the year before. The highest annual figure on record is -103.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -103.6% | +11.5 |
| FY2024 | Oct 31, 2024 | -115.1% | +33.4 |
| FY2023 | Oct 31, 2023 | -148.5% | −12.3 |
| FY2022 | Oct 31, 2022 | -136.2% | +91.4 |
| FY2021 | Oct 31, 2021 | -227.7% | +179.4 |
| FY2020 | Oct 31, 2020 | -407.0% | −302.7 |
| FY2019 | Oct 31, 2019 | -104.4% | +257.5 |
| FY2018 | Oct 31, 2018 | -361.8% | +1154.6 |
| FY2017 | Oct 31, 2017 | -1516.5% | −952.2 |
| FY2016 | Oct 31, 2016 | -564.3% | −60.1 |
| FY2015 | Oct 31, 2015 | -504.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -19.8% | +101.5 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -60.7% | +54.2 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -40.4% | +97.9 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -158.6% | −57.9 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -121.3% | −34.7 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -115.0% | +3.5 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -138.3% | +82.1 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -100.7% | +60.5 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -86.6% | −14.1 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -118.4% | −15.8 |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | -220.4% | −163.2 |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | -161.2% | −59.4 |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -72.5% | +450.9 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -102.6% | +581.1 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -57.2% | +165.8 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | -101.8% | −3.0 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -523.4% | −402.1 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -683.8% | −625.2 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -222.9% | −54.3 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -98.8% | +47.4 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -121.4% | +2423.6 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -58.6% | +40.7 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -168.6% | +173.1 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -146.2% | +394.8 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -2544.9% | −686.5 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -99.3% | +724812.3 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -341.7% | +992.2 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -541.0% | +119.2 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -1858.4% | −1474.2 |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -724911.6% | −724589.0 |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -1333.9% | −1053.5 |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -660.1% | +533.5 |
| Q2 FY2016CQ1 2016 | Apr 30, 2016 | -384.2% | – |
| Q1 FY2016CQ4 2015 | Jan 31, 2016 | -322.7% | – |
| Q4 FY2015CQ3 2015 | Oct 31, 2015 | -280.4% | – |
| Q3 FY2015CQ2 2015 | Jul 31, 2015 | -1193.7% | – |
See a number that looks wrong?